News
Displaying 51–60 of 504
-
ARVO 2024 Highlight: New Gene Linked to RP in People with African Ancestry
Research NewsThe discovery will help geneticists diagnose more RP patients with African descent.
-
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Research NewsMutations in PDE6B are a leading cause of retinitis pigmentosa.
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Foundation Fighting Blindness To Host Annual 2024 Gala Night for Sight
Foundation NewsThe May 9th gala will raise awareness and fund research leading to treatments and cures for blinding diseases.
-
SalioGen Developing Novel Gene Insertion Therapy for Stargardt Disease
Research NewsThe company’s innovative Gene Coding™ platform enables seamless insertion of DNA into selective genomic locations.
-
Phase 3 Clinical Trial of NAC Launched for RP Patients
Research NewsThe drug is thought to work independent of the mutated gene causing RP.
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
Research NewsThe emerging treatment is designed to work independent of the patient’s mutated gene.
-
Foundation News
The Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund hosted their annual Investing in Cures Summit (ICS) on March 8 and 9, 2024, to highlight the progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
-
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
Research NewsThe company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
.png)
